The Prognostic Value of Systemic Immune-Inflammation Index Supporting Age-Adjusted Charlson Comorbidity Index in Non-Small Cell Lung Cancer Patients with First-Line Platinum-Based Chemotherapy
SII was proven to be valuable in predicting OS and, when complemented by ACCI, can help tailor prognostic assessment and treatment strategies in assessing the survival of NSCLC patients with first-line PBC.
Authors
- Yi Bai (ORCID: https://orcid.org/0000-0002-1179-3734)
- Qing Zhu (ORCID: https://orcid.org/0000-0003-2803-9954)
- Qun Dai (ORCID: https://orcid.org/0000-0003-2163-4283)
- Mei-Fang Liu (ORCID: https://orcid.org/0009-0003-6391-1039)
- Yujie Gao (ORCID: https://orcid.org/0000-0002-3168-6637)
- Yi-yun Sheng (ORCID: https://orcid.org/0009-0006-7104-8126)
Institutions
- Nanchang University (CN)
Publication Details
- Journal
- International Journal of General Medicine
- Published
- 2024-12-01
- DOI
- https://doi.org/10.2147/ijgm.s486674
- Primary Topic
- Inflammatory Biomarkers in Disease Prognosis
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Natural Science Foundation of Jiangxi Province